ArticleFrontiers in nutrition2026
Gentiopicroside alleviates type 2 diabetes mellitus by attenuating oxidative stress and reshaping gut microbiota in high-fat diet and streptozotocin-induced mice.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The rising incidence of T2DM, along with the limited efficacy and side effects of current drugs, demands new therapies. Gentiopicroside (GPS) has been shown to improve T2DM and its chronic complications; however, whether these effects are related to modulation of the gut microbiota (GM) remains unclear. Herein, the relationship between the therapeutic effects of GPS on T2DM and GM alterations was investigated using a C57BL/6J mouse model of T2DM induced by a high-fat diet combined with streptozotocin (STZ). Methods: A T2DM model was induced in C57BL/6J mice by high-fat diet combined with STZ. Biochemical methods were used to determine glucose metabolism and oxidative stress-related indices in serum and liver; Western blot was employed to detect the expression of proteins related to the Nrf2/Keap1 signaling pathway in the liver; 16S rRNA high-throughput sequencing was used to detect and analyze gut microbiota in mouse feces. Results: The results demonstrated that 8 weeks of GPS supplementation significantly reduced blood glucose and insulin levels, improved glucose tolerance and insulin resistance, alleviated liver pathology, enhanced the activity of antioxidant enzymes in serum and liver, increased antioxidant substance levels, and decreased MDA content. Moreover, GPS markedly upregulated the expression protein of Nrf2, HO-1, and NQO1, while downregulating the Keap1 expression in the liver. High-throughput 16S rRNA sequencing further revealed that GPS significantly increased the Chao1 index and Observed_otus index, showed a trend of improving indices such as Shannon, Simpson, Pielou-e, Goods-coverage, and improved Conclusion: In conclusion, these results indicated that GPS can reshape the structural composition and diversity of GM, activate the hepatic Nrf2/Keap1 pathway, and maintain glucose homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.